Cantor Fitzgerald Reiterate Hold Following Ligand Pharma's (LGND) Strong Q1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Streetinsider.com's Hot Lunchtime Reads 5/11: (LGND) (AAPL) (RL) (JPM) (OIL)
May 11, 2015 12:12 PM EDTThe following is a list of notable articles to help get you through the lunch hour:Apple (AAPL) CEO Cook Joins Sina's Weibo in China Social Media Push ->... More
Ligand Pharma (LGND) PT Lifted to $127 at Roth Capital Following Q1 and as Pipeline Expands
May 11, 2015 11:34 AM EDTRoth Capital analyst Joseph Pantginis reiterated a Buy rating and boosted his price target on Ligand Pharma (NASDAQ: LGND) to $127.00 (from $116.00) following Q1 results.
LGND reported non-GAAP EPS of $0.33 vs. consensus of $0.27. LGND reported total revenues of $14.602 million vs. our estimate of $13.48 million and consensus... More
Ligand Pharma (LGND) Tops Q1 EPS by 6c
May 11, 2015 8:31 AM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.33, $0.06 better than the analyst estimate of $0.27. Revenue for the quarter came in at $14.6 million versus the consensus estimate of $13.5 million.
Ligand Pharma sees FY2015 EPS of $2.14-$2.18, versus the consensus of $2.13. Ligand Pharma sees FY2015... More
